Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)

v3.20.2
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Series C Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Income / Loss
Total
Beginning balance, shares at Mar. 31, 2019 2 1,316,335        
Beginning balance, value at Mar. 31, 2019 $ 2 $ 184,074 $ (169,238) $ (4,349) $ 10,489
Cumulative adjustment resulting from adoption of ASU (59) (59)
Stock based compensation related to common stock restricted stock grants, shares 835        
Stock based compensation related to common stock restricted stock grants, value 20 20
Stock-based compensation expense, net of forfeitures 272   272
Foreign currency translation adjustment 67 67
Net income 715 715
Ending balance, shares at Jun. 30, 2019 2 1,317,170        
Ending balance, value at Jun. 30, 2019 $ 2 184,366 (168,582) (4,282) 11,504
Stock based compensation related to common stock restricted stock grants, shares 834        
Stock based compensation related to common stock restricted stock grants, value 9 9
Stock-based compensation expense, net of forfeitures 124 124
Foreign currency translation adjustment (163) (163)
Net income (1,203) (1,203)
Ending balance, shares at Sep. 30, 2019 2 1,318,004        
Ending balance, value at Sep. 30, 2019 $ 2 184,499 (169,785) (4,445) 10,271
Beginning balance, shares at Mar. 31, 2020 2 1,777,483        
Beginning balance, value at Mar. 31, 2020 $ 2 186,559 (172,246) (5,610) 8,705
Stock based compensation related to common stock restricted stock grants, shares 3,086        
Stock based compensation related to common stock restricted stock grants, value 18 18
Stock-based compensation expense, net of forfeitures 45   45
Issuance of common stock due to warrant exercises, shares 169,167        
Issuance of common stock due to warrant exercises, value 1,490 1,490
Conversion of Series C convertible preferred stock into common stock, shares (2) 17,222        
Conversion of Series C convertible preferred stock into common stock, value
Foreign currency translation adjustment 167 167
Net income 240 240
Ending balance, shares at Jun. 30, 2020 1,966,958        
Ending balance, value at Jun. 30, 2020 $ 2 188,112 (172,006) (5,443) 10,665
Stock-based compensation expense, net of forfeitures 160 160
Issuance of common stock due to options exercises, shares 74,451        
Issuance of common stock due to options exercises, value 429 429
Foreign currency translation adjustment 188 188
Net income 120 120
Ending balance, shares at Sep. 30, 2020 2,041,409        
Ending balance, value at Sep. 30, 2020 $ 2 $ 188,701 $ (171,886) $ (5,255) $ 11,562